Cargando…
Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations
The success of antibodies targeting Programmed cell death protein 1 (PD-1) and its ligand L1 (PD-L1) in cancer treatment and the need for improving response rates has led to an increased demand for the development of combination therapies with anti-PD-1/PD-L1 blockers as a backbone. As more and more...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485537/ https://www.ncbi.nlm.nih.gov/pubmed/34598713 http://dx.doi.org/10.1186/s13046-021-02111-5 |